Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MYCN amplification plus 1p36 loss of heterozygosity predicts ultra high risk in bone marrow metastatic neuroblastoma

9 Feb 2022

Abstract excerpt

BACKGROUND: This study aimed to better understand the prognostic effect of multiple genetic markers and identify more subpopulations at ultra high risk of poor outcome in bone marrow (BM) metastatic neuroblastoma (NB). METHODS: We screened the MYCN, 1p36 and 11q23 loss of heterozygosity (LOH) statuses of 154 patients by interphase fluorescence in situ hybridization of BM cells. The clinical characteristics of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Lung Cancer Research Studies
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35137546
DOI: 10.1002/cam4.4583

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MYCN amplification plus 1p36 loss of heterozygosity predicts ultra high risk in bone marrow metastatic neuroblastomaPMID 35137546Read ↗

Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Children’s Cancer Group StudySemantic proximity Read ↗

Chromosome 1p and 11q Deletions and Outcome in NeuroblastomaSemantic proximity Read ↗

MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastomaSemantic proximity Read ↗

Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplificationSemantic proximity Read ↗

Comprehensive analysis of chromosome 1p deletions in neuroblastoma.Semantic proximity Read ↗

Identification of patient subgroups with markedly disparate rates of <i>MYCN</i> amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group projectSemantic proximity Read ↗

Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.Semantic proximity Read ↗

High Genomic Instability Predicts Survival in Metastatic High-Risk NeuroblastomaSemantic proximity Read ↗

Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma.Semantic proximity Read ↗

Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology GroupSemantic proximity Read ↗

Integrative Genomics Identifies Distinct Molecular Classes of Neuroblastoma and Shows That Multiple Genes Are Targeted by Regional Alterations in DNA Copy NumberSemantic proximity Read ↗

Identification of a novel recurrent 1q42.2‐1qter deletion in high risk <i>MYCN</i> single copy 11q deleted neuroblastomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.